STOCK TITAN

Calithera Biosciences Inc - CALA STOCK NEWS

Welcome to our dedicated news page for Calithera Biosciences (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on Calithera Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calithera Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calithera Biosciences's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.84%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.13%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.95%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.95%
Tags
offering
Calithera Biosciences Inc

Nasdaq:CALA

CALA Rankings

CALA Stock Data

97.45k
4.78M
1.07%
0%
8.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About CALA

calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.